| Exudative age-related macular degeneration
Beovu vs Byooviz
Side-by-side clinical, coverage, and cost comparison for exudative age-related macular degeneration.Deep comparison between: Beovu vs Byooviz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsByooviz has a higher rate of injection site reactions vs Beovu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Byooviz but not Beovu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beovu
Byooviz
At A Glance
Intravitreal injection
Every 8-12 weeks (maintenance)
VEGF-A inhibitor
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Exudative age-related macular degeneration
- Retinal Vein Occlusion
- Myopic choroidal neovascularization
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection monthly (every 25-31 days) for first 3 doses, followed by 6 mg every 8-12 weeks.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 6 weeks (every 39-45 days) for first 5 doses, followed by 6 mg every 8-12 weeks.
Exudative age-related macular degeneration 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); may reduce to less frequent dosing after 3 initial monthly doses with regular assessment, or once every 3 months after 4 monthly doses.
Retinal Vein Occlusion 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); patients should be treated monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL) by intravitreal injection once monthly for up to 3 months; retreatment as needed.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any excipient in BEOVU
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab products or any excipient in BYOOVIZ
Adverse Reactions
Most common (>=1%) Vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, eye pain, intraocular inflammation, intraocular pressure increased, retinal hemorrhage, vitreous detachment, conjunctivitis, retinal pigment epithelial tear, corneal abrasion, hypersensitivity, punctate keratitis, retinal tear, endophthalmitis, blindness, retinal artery occlusion, retinal detachment, conjunctival hyperemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitreous hemorrhage
Serious Endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, intraocular pressure increase, thromboembolic events, hypersensitivity
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, intraocular pressure increased, vitreous detachment, intraocular inflammation, cataract, nasopharyngitis, headache, bronchitis, arthralgia, upper respiratory tract infection
Serious Endophthalmitis, retinal detachments, thromboembolic events, serious intraocular inflammation
Postmarketing Tear of retinal pigment epithelium (neovascular AMD patients)
Pharmacology
VEGF-A inhibitor; brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment that binds the three major isoforms of VEGF-A (VEGF110, VEGF121, VEGF165), blocking VEGFR-1 and VEGFR-2 interaction to suppress endothelial cell proliferation, neovascularization, and vascular permeability.
VEGF-A antagonist; ranibizumab products bind to the receptor binding site of active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beovu
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Byooviz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Beovu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Byooviz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beovu
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Byooviz
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableByooviz Administration Copay Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ByoovizView full Byooviz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.